ID   K1C18_HUMAN             Reviewed;         430 AA.
AC   P05783; Q53G38; Q5U0N8; Q9BW26;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JUN-2023, entry version 239.
DE   RecName: Full=Keratin, type I cytoskeletal 18;
DE   AltName: Full=Cell proliferation-inducing gene 46 protein;
DE   AltName: Full=Cytokeratin-18;
DE            Short=CK-18;
DE   AltName: Full=Keratin-18;
DE            Short=K18;
GN   Name=KRT18; Synonyms=CYK18; ORFNames=PIG46;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=2434380; DOI=10.1111/j.1432-0436.1986.tb00411.x;
RA   Oshima R.G., Millan J.L., Cecena G.;
RT   "Comparison of mouse and human keratin 18: a component of intermediate
RT   filaments expressed prior to implantation.";
RL   Differentiation 33:61-68(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kim J.W.;
RT   "Identification of a cell proliferation-inducing gene.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, Colon, Pancreas, Placenta, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-167.
RX   PubMed=2454392; DOI=10.1128/mcb.8.4.1540-1550.1988;
RA   Kulesh D.A., Oshima R.G.;
RT   "Cloning of the human keratin 18 gene and its expression in nonepithelial
RT   mouse cells.";
RL   Mol. Cell. Biol. 8:1540-1550(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-430, AND TISSUE SPECIFICITY.
RC   TISSUE=Vulva;
RX   PubMed=2434381; DOI=10.1111/j.1432-0436.1986.tb00412.x;
RA   Leube R.E., Bosch F.X., Romano V., Zimbelmann R., Hofler H., Franke W.W.;
RT   "Cytokeratin expression in simple epithelia. III. Detection of mRNAs
RT   encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by
RT   hybridization with cDNA sequences in vitro and in situ.";
RL   Differentiation 33:69-85(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 199-430, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=2422083; DOI=10.1111/j.1432-0436.1986.tb00787.x;
RA   Romano V., Hatzfeld M., Magin T.M., Zimbelmann R., Franke W.W., Maier G.,
RA   Ponstingl H.;
RT   "Cytokeratin expression in simple epithelia. I. Identification of mRNA
RT   coding for human cytokeratin no. 18 by a cDNA clone.";
RL   Differentiation 30:244-253(1986).
RN   [9]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [10]
RP   GLYCOSYLATION.
RX   PubMed=1371281; DOI=10.1016/s0021-9258(19)50611-1;
RA   Chou C.F., Smith A.J., Omary M.B.;
RT   "Characterization and dynamics of O-linked glycosylation of human
RT   cytokeratin 8 and 18.";
RL   J. Biol. Chem. 267:3901-3906(1992).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-53, AND MUTAGENESIS OF SER-2; SER-7;
RP   SER-10; SER-15; SER-18; SER-23; SER-30; SER-31; SER-34; SER-42; SER-44;
RP   SER-47; SER-49; SER-51 AND SER-53.
RX   PubMed=7523419; DOI=10.1083/jcb.127.1.161;
RA   Ku N.O., Omary M.B.;
RT   "Identification of the major physiologic phosphorylation site of human
RT   keratin 18: potential kinases and a role in filament reorganization.";
RL   J. Cell Biol. 127:161-171(1994).
RN   [12]
RP   GLYCOSYLATION AT SER-30; SER-31 AND SER-49, MUTAGENESIS OF SER-30; SER-31
RP   AND SER-49, CLEAVAGE OF INITIATOR METHIONINE, AND ACETYLATION AT SER-2.
RX   PubMed=7538124; DOI=10.1074/jbc.270.20.11820;
RA   Ku N.-O., Omary M.B.;
RT   "Identification and mutational analysis of the glycosylation sites of human
RT   keratin 18.";
RL   J. Biol. Chem. 270:11820-11827(1995).
RN   [13]
RP   FUNCTION, AND MUTAGENESIS OF ARG-90.
RX   PubMed=8522591; DOI=10.1083/jcb.131.5.1303;
RA   Ku N.O., Michie S., Oshima R.G., Omary M.B.;
RT   "Chronic hepatitis, hepatocyte fragility, and increased soluble
RT   phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved
RT   arginine mutant.";
RL   J. Cell Biol. 131:1303-1314(1995).
RN   [14]
RP   PHOSPHORYLATION, AND INTERACTION WITH YWHAE; YWHAH AND YWHAZ.
RX   PubMed=8609167; DOI=10.1083/jcb.133.2.345;
RA   Liao J., Omary M.B.;
RT   "14-3-3 proteins associate with phosphorylated simple epithelial keratins
RT   during cell cycle progression and act as a solubility cofactor.";
RL   J. Cell Biol. 133:345-357(1996).
RN   [15]
RP   FUNCTION, CLEAVAGE BY CASPASES, AND MUTAGENESIS OF SER-53 AND ASP-238.
RX   PubMed=9298992; DOI=10.1083/jcb.138.6.1379;
RA   Caulin C., Salvesen G.S., Oshima R.G.;
RT   "Caspase cleavage of keratin 18 and reorganization of intermediate
RT   filaments during epithelial cell apoptosis.";
RL   J. Cell Biol. 138:1379-1394(1997).
RN   [16]
RP   FUNCTION, INTERACTION WITH YWHAE AND YWHAZ, PHOSPHORYLATION AT SER-34, AND
RP   MUTAGENESIS OF SER-34 AND SER-53.
RX   PubMed=9524113; DOI=10.1093/emboj/17.7.1892;
RA   Ku N.O., Liao J., Omary M.B.;
RT   "Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3
RT   proteins.";
RL   EMBO J. 17:1892-1906(1998).
RN   [17]
RP   INTERACTION WITH PNN.
RX   PubMed=10809736; DOI=10.1074/jbc.275.20.14910;
RA   Shi J., Sugrue S.P.;
RT   "Dissection of protein linkage between keratins and pinin, a protein with
RT   dual location at desmosome-intermediate filament complex and in the
RT   nucleus.";
RL   J. Biol. Chem. 275:14910-14915(2000).
RN   [18]
RP   INTERACTION WITH DNAJB6.
RX   PubMed=10954706; DOI=10.1074/jbc.m003492200;
RA   Izawa I., Nishizawa M., Ohtakara K., Ohtsuka K., Inada H., Inagaki M.;
RT   "Identification of Mrj, a DnaJ/Hsp40 family protein, as a keratin 8/18
RT   filament regulatory protein.";
RL   J. Biol. Chem. 275:34521-34527(2000).
RN   [19]
RP   INTERACTION WITH PKP1; PKP2 AND KRT8.
RX   PubMed=10852826; DOI=10.1242/jcs.113.13.2471;
RA   Hofmann I., Mertens C., Brettel M., Nimmrich V., Schnoelzer M.,
RA   Herrmann H.;
RT   "Interaction of plakophilins with desmoplakin and intermediate filament
RT   proteins: an in vitro analysis.";
RL   J. Cell Sci. 113:2471-2483(2000).
RN   [20]
RP   INTERACTION WITH TRADD.
RX   PubMed=11684708; DOI=10.1083/jcb.200103078;
RA   Inada H., Izawa I., Nishizawa M., Fujita E., Kiyono T., Takahashi T.,
RA   Momoi T., Inagaki M.;
RT   "Keratin attenuates tumor necrosis factor-induced cytotoxicity through
RT   association with TRADD.";
RL   J. Cell Biol. 155:415-426(2001).
RN   [21]
RP   ASSOCIATION WITH KRT8.
RX   PubMed=14756564; DOI=10.1021/bi035072s;
RA   Waseem A., Karsten U., Leigh I.M., Purkis P., Waseem N.H., Lane E.B.;
RT   "Conformational changes in the rod domain of human keratin 8 following
RT   heterotypic association with keratin 18 and its implication for filament
RT   stability.";
RL   Biochemistry 43:1283-1295(2004).
RN   [22]
RP   PHOSPHORYLATION AT SER-34 AND SER-53.
RX   PubMed=15368451; DOI=10.1002/hep.20277;
RA   Toivola D.M., Ku N.O., Resurreccion E.Z., Nelson D.R., Wright T.L.,
RA   Omary M.B.;
RT   "Keratin 8 and 18 hyperphosphorylation is a marker of progression of human
RT   liver disease.";
RL   Hepatology 40:459-466(2004).
RN   [23]
RP   FUNCTION, INTERACTION WITH MUTATED CFTR, AND SUBCELLULAR LOCATION.
RX   PubMed=15529338; DOI=10.1002/pmic.200400850;
RA   Davezac N., Tondelier D., Lipecka J., Fanen P., Demaugre F., Debski J.,
RA   Dadlez M., Schrattenholz A., Cahill M.A., Edelman A.;
RT   "Global proteomic approach unmasks involvement of keratins 8 and 18 in the
RT   delivery of cystic fibrosis transmembrane conductance regulator
RT   (CFTR)/deltaF508-CFTR to the plasma membrane.";
RL   Proteomics 4:3833-3844(2004).
RN   [24]
RP   INTERACTION WITH TCHP.
RX   PubMed=15731013; DOI=10.1242/jcs.01667;
RA   Nishizawa M., Izawa I., Inoko A., Hayashi Y., Nagata K., Yokoyama T.,
RA   Usukura J., Inagaki M.;
RT   "Identification of trichoplein, a novel keratin filament-binding protein.";
RL   J. Cell Sci. 118:1081-1090(2005).
RN   [25]
RP   INTERACTION WITH HEPATITIS C VIRUS CORE PROTEIN (MICROBIAL INFECTION).
RX   PubMed=15846844; DOI=10.1002/pmic.200401093;
RA   Kang S.-M., Shin M.-J., Kim J.-H., Oh J.-W.;
RT   "Proteomic profiling of cellular proteins interacting with the hepatitis C
RT   virus core protein.";
RL   Proteomics 5:2227-2237(2005).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [27]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-53.
RX   PubMed=16424149; DOI=10.1124/jpet.105.097667;
RA   Lipecka J., Norez C., Bensalem N., Baudouin-Legros M., Planelles G.,
RA   Becq F., Edelman A., Davezac N.;
RT   "Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance
RT   regulator) by curcumin: involvement of the keratin 18 network.";
RL   J. Pharmacol. Exp. Ther. 317:500-505(2006).
RN   [28]
RP   FUNCTION, TISSUE SPECIFICITY, PHOSPHORYLATION, AND INDUCTION.
RX   PubMed=17213200; DOI=10.1074/jbc.m604068200;
RA   Wang L., Srinivasan S., Theiss A.L., Merlin D., Sitaraman S.V.;
RT   "Interleukin-6 induces keratin expression in intestinal epithelial cells:
RT   potential role of keratin-8 in interleukin-6-induced barrier function
RT   alterations.";
RL   J. Biol. Chem. 282:8219-8227(2007).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-34; SER-42; SER-60;
RP   THR-302 AND SER-399, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-131 AND LYS-426, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   GLYCOSYLATION AT SER-30; SER-31 AND SER-49.
RX   PubMed=20729549; DOI=10.1074/jbc.m109.098996;
RA   Srikanth B., Vaidya M.M., Kalraiya R.D.;
RT   "O-GlcNAcylation determines the solubility, filament organization, and
RT   stability of keratins 8 and 18.";
RL   J. Biol. Chem. 285:34062-34071(2010).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7; SER-15; SER-34; SER-42;
RP   SER-60; THR-65; SER-100; SER-319; SER-399 AND THR-404, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [37]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=22002106; DOI=10.1074/mcp.m111.013680;
RA   Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.;
RT   "Systematic analysis of protein pools, isoforms, and modifications
RT   affecting turnover and subcellular localization.";
RL   Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   INTERACTION WITH FAM83H.
RX   PubMed=23902688; DOI=10.1242/jcs.129684;
RA   Kuga T., Kume H., Kawasaki N., Sato M., Adachi J., Shiromizu T.,
RA   Hoshino I., Nishimori T., Matsubara H., Tomonaga T.;
RT   "A novel mechanism of keratin cytoskeleton organization through casein
RT   kinase Ialpha and FAM83H in colorectal cancer.";
RL   J. Cell Sci. 126:4721-4731(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-18; SER-34; SER-49;
RP   THR-52; SER-60; SER-93; SER-305; SER-319; SER-323 AND SER-399, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   IDENTIFICATION IN A COMPLEX WITH KRT8, AND INTERACTION WITH KRT8 AND PLEC.
RX   PubMed=24940650; DOI=10.1038/jid.2014.255;
RA   Bouameur J.E., Favre B., Fontao L., Lingasamy P., Begre N., Borradori L.;
RT   "Interaction of plectin with keratins 5 and 14: dependence on several
RT   plectin domains and keratin quaternary structure.";
RL   J. Invest. Dermatol. 134:2776-2783(2014).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-65; SER-177; SER-305;
RP   SER-398; SER-399; SER-401 AND THR-404, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-45 AND ARG-55, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [44]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-426, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [45]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-81; LYS-247; LYS-370; LYS-372;
RP   LYS-417 AND LYS-426, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [46]
RP   VARIANT CIRRH LEU-128.
RX   PubMed=9011570; DOI=10.1172/jci119127;
RA   Ku N.-O., Wright T.L., Terrault N.A., Gish R., Omary M.B.;
RT   "Mutation of human keratin 18 in association with cryptogenic cirrhosis.";
RL   J. Clin. Invest. 99:19-23(1997).
RN   [47]
RP   VARIANTS CIRRH ALA-103; LEU-128; GLN-261 AND ARG-340, AND VARIANT THR-230.
RX   PubMed=12724528; DOI=10.1073/pnas.0936165100;
RA   Ku N.-O., Darling J.M., Krams S.M., Esquivel C.O., Keeffe E.B.,
RA   Sibley R.K., Lee Y.M., Wright T.L., Omary M.B.;
RT   "Keratin 8 and 18 mutations are risk factors for developing liver disease
RT   of multiple etiologies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6063-6068(2003).
CC   -!- FUNCTION: Involved in the uptake of thrombin-antithrombin complexes by
CC       hepatic cells (By similarity). When phosphorylated, plays a role in
CC       filament reorganization. Involved in the delivery of mutated CFTR to
CC       the plasma membrane. Together with KRT8, is involved in interleukin-6
CC       (IL-6)-mediated barrier protection. {ECO:0000250,
CC       ECO:0000269|PubMed:15529338, ECO:0000269|PubMed:16424149,
CC       ECO:0000269|PubMed:17213200, ECO:0000269|PubMed:7523419,
CC       ECO:0000269|PubMed:8522591, ECO:0000269|PubMed:9298992,
CC       ECO:0000269|PubMed:9524113}.
CC   -!- SUBUNIT: Heterotetramer of two type I and two type II keratins. KRT18
CC       associates with KRT8 (PubMed:10852826, PubMed:24940650). Interacts with
CC       PLEC isoform 1C, when in a heterodimer with KRT8 (PubMed:24940650).
CC       Interacts with the thrombin-antithrombin complex (By similarity).
CC       Interacts with PNN and mutated CFTR. Interacts with YWHAE, YWHAH and
CC       YWHAZ only when phosphorylated. Interacts with DNAJB6, TCHP and TRADD.
CC       Interacts with FAM83H (PubMed:23902688). Interacts with EPPK1 (By
CC       similarity). Interacts with PKP1 and PKP2 (PubMed:10852826).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P05784,
CC       ECO:0000269|PubMed:10809736, ECO:0000269|PubMed:10852826,
CC       ECO:0000269|PubMed:10954706, ECO:0000269|PubMed:11684708,
CC       ECO:0000269|PubMed:15529338, ECO:0000269|PubMed:15731013,
CC       ECO:0000269|PubMed:23902688, ECO:0000269|PubMed:24940650,
CC       ECO:0000269|PubMed:8609167, ECO:0000269|PubMed:9524113}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis C virus/HCV
CC       core protein. {ECO:0000269|PubMed:15846844}.
CC   -!- INTERACTION:
CC       P05783; Q14457: BECN1; NbExp=2; IntAct=EBI-297888, EBI-949378;
CC       P05783; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-297888, EBI-8643161;
CC       P05783; Q8IYE0-2: CCDC146; NbExp=3; IntAct=EBI-297888, EBI-10247802;
CC       P05783; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-297888, EBI-10175300;
CC       P05783; O75190: DNAJB6; NbExp=6; IntAct=EBI-297888, EBI-1053164;
CC       P05783; Q5JVL4: EFHC1; NbExp=3; IntAct=EBI-297888, EBI-743105;
CC       P05783; Q08379: GOLGA2; NbExp=7; IntAct=EBI-297888, EBI-618309;
CC       P05783; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-297888, EBI-2514791;
CC       P05783; A0A0S2Z4Q4: HGS; NbExp=3; IntAct=EBI-297888, EBI-16429135;
CC       P05783; O14964: HGS; NbExp=7; IntAct=EBI-297888, EBI-740220;
CC       P05783; P42858: HTT; NbExp=6; IntAct=EBI-297888, EBI-466029;
CC       P05783; Q9Y6K9: IKBKG; NbExp=3; IntAct=EBI-297888, EBI-81279;
CC       P05783; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-297888, EBI-14069005;
CC       P05783; P02538: KRT6A; NbExp=3; IntAct=EBI-297888, EBI-702198;
CC       P05783; P48668: KRT6C; NbExp=4; IntAct=EBI-297888, EBI-2564105;
CC       P05783; Q3SY84: KRT71; NbExp=3; IntAct=EBI-297888, EBI-2952676;
CC       P05783; Q5XKE5: KRT79; NbExp=3; IntAct=EBI-297888, EBI-2514135;
CC       P05783; P05787: KRT8; NbExp=16; IntAct=EBI-297888, EBI-297852;
CC       P05783; Q14533: KRT81; NbExp=3; IntAct=EBI-297888, EBI-739648;
CC       P05783; O75022: LILRB3; NbExp=3; IntAct=EBI-297888, EBI-2830524;
CC       P05783; Q9BQ69: MACROD1; NbExp=7; IntAct=EBI-297888, EBI-5324932;
CC       P05783; P07196: NEFL; NbExp=3; IntAct=EBI-297888, EBI-475646;
CC       P05783; Q9Y5B8: NME7; NbExp=4; IntAct=EBI-297888, EBI-744782;
CC       P05783; Q13835-2: PKP1; NbExp=4; IntAct=EBI-297888, EBI-9087684;
CC       P05783; A0A0S2Z505: PSTPIP2; NbExp=3; IntAct=EBI-297888, EBI-16437709;
CC       P05783; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-297888, EBI-1504830;
CC       P05783; Q8N0S2: SYCE1; NbExp=3; IntAct=EBI-297888, EBI-6872807;
CC       P05783; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-297888, EBI-750487;
CC       P05783; Q15628: TRADD; NbExp=11; IntAct=EBI-297888, EBI-359215;
CC       P05783; Q99816: TSG101; NbExp=4; IntAct=EBI-297888, EBI-346882;
CC       P05783; B7UM99: tir; Xeno; NbExp=5; IntAct=EBI-297888, EBI-2504426;
CC   -!- SUBCELLULAR LOCATION: Nucleus matrix {ECO:0000250|UniProtKB:Q5BJY9}.
CC       Cytoplasm, perinuclear region. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:22002106}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q5BJY9}.
CC   -!- TISSUE SPECIFICITY: Expressed in colon, placenta, liver and very weakly
CC       in exocervix. Increased expression observed in lymph nodes of breast
CC       carcinoma. {ECO:0000269|PubMed:17213200, ECO:0000269|PubMed:2422083,
CC       ECO:0000269|PubMed:2434380, ECO:0000269|PubMed:2434381}.
CC   -!- INDUCTION: By IL6/interleukin-6. {ECO:0000269|PubMed:17213200}.
CC   -!- PTM: Phosphorylation at Ser-34 increases during mitosis.
CC       Hyperphosphorylated at Ser-53 in diseased cirrhosis liver.
CC       Phosphorylation increases by IL-6. {ECO:0000269|PubMed:15368451,
CC       ECO:0000269|PubMed:16424149, ECO:0000269|PubMed:17213200,
CC       ECO:0000269|PubMed:7523419, ECO:0000269|PubMed:8609167,
CC       ECO:0000269|PubMed:9524113}.
CC   -!- PTM: Proteolytically cleaved by caspases during epithelial cell
CC       apoptosis. Cleavage occurs at Asp-238 by either caspase-3, caspase-6 or
CC       caspase-7. {ECO:0000269|PubMed:9298992}.
CC   -!- PTM: O-GlcNAcylation increases solubility, and decreases stability by
CC       inducing proteasomal degradation.
CC   -!- DISEASE: Cirrhosis (CIRRH) [MIM:215600]: A liver disease characterized
CC       by severe panlobular liver-cell swelling with Mallory body formation,
CC       prominent pericellular fibrosis, and marked deposits of copper.
CC       Clinical features include abdomen swelling, jaundice and pulmonary
CC       hypertension. {ECO:0000269|PubMed:12724528,
CC       ECO:0000269|PubMed:9011570}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of cytoskeletal and microfibrillar
CC       keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12881; CAA31375.1; -; mRNA.
DR   EMBL; AY762101; AAX07828.1; -; mRNA.
DR   EMBL; BT019412; AAV38219.1; -; mRNA.
DR   EMBL; AK223093; BAD96813.1; -; mRNA.
DR   EMBL; BC000180; AAH00180.1; -; mRNA.
DR   EMBL; BC000698; AAH00698.1; -; mRNA.
DR   EMBL; BC004253; AAH04253.1; -; mRNA.
DR   EMBL; BC008636; AAH08636.1; -; mRNA.
DR   EMBL; BC020982; AAH20982.1; -; mRNA.
DR   EMBL; BC072017; AAH72017.1; -; mRNA.
DR   EMBL; AF179904; AAA59461.1; -; Genomic_DNA.
DR   EMBL; X12883; CAA31377.1; -; mRNA.
DR   EMBL; X12876; CAA31369.1; -; mRNA.
DR   CCDS; CCDS31809.1; -.
DR   PIR; S05481; S05481.
DR   RefSeq; NP_000215.1; NM_000224.2.
DR   RefSeq; NP_954657.1; NM_199187.1.
DR   AlphaFoldDB; P05783; -.
DR   SMR; P05783; -.
DR   BioGRID; 110073; 366.
DR   ComplexPortal; CPX-5661; Keratin-8 - Keratin-18 dimer complex.
DR   DIP; DIP-633N; -.
DR   IntAct; P05783; 115.
DR   MINT; P05783; -.
DR   STRING; 9606.ENSP00000373487; -.
DR   GlyConnect; 312; 3 N-Linked glycans (1 site), 1 O-GlcNAc glycan (2 sites).
DR   GlyCosmos; P05783; 7 sites, 3 glycans.
DR   GlyGen; P05783; 19 sites, 2 N-linked glycans (1 site), 2 O-linked glycans (18 sites).
DR   iPTMnet; P05783; -.
DR   MetOSite; P05783; -.
DR   PhosphoSitePlus; P05783; -.
DR   SwissPalm; P05783; -.
DR   BioMuta; KRT18; -.
DR   DMDM; 125083; -.
DR   SWISS-2DPAGE; P05783; -.
DR   CPTAC; CPTAC-1518; -.
DR   CPTAC; CPTAC-1519; -.
DR   EPD; P05783; -.
DR   jPOST; P05783; -.
DR   MassIVE; P05783; -.
DR   MaxQB; P05783; -.
DR   PaxDb; P05783; -.
DR   PeptideAtlas; P05783; -.
DR   PRIDE; P05783; -.
DR   ProteomicsDB; 51857; -.
DR   TopDownProteomics; P05783; -.
DR   ABCD; P05783; 4 sequenced antibodies.
DR   Antibodypedia; 271; 3899 antibodies from 57 providers.
DR   DNASU; 3875; -.
DR   Ensembl; ENST00000388835.4; ENSP00000373487.3; ENSG00000111057.11.
DR   Ensembl; ENST00000388837.6; ENSP00000373489.2; ENSG00000111057.11.
DR   GeneID; 3875; -.
DR   KEGG; hsa:3875; -.
DR   MANE-Select; ENST00000388835.4; ENSP00000373487.3; NM_000224.3; NP_000215.1.
DR   UCSC; uc001sbe.4; human.
DR   AGR; HGNC:6430; -.
DR   CTD; 3875; -.
DR   DisGeNET; 3875; -.
DR   GeneCards; KRT18; -.
DR   HGNC; HGNC:6430; KRT18.
DR   HPA; ENSG00000111057; Low tissue specificity.
DR   MalaCards; KRT18; -.
DR   MIM; 148070; gene.
DR   MIM; 215600; phenotype.
DR   neXtProt; NX_P05783; -.
DR   OpenTargets; ENSG00000111057; -.
DR   PharmGKB; PA30217; -.
DR   VEuPathDB; HostDB:ENSG00000111057; -.
DR   eggNOG; ENOG502QUS8; Eukaryota.
DR   GeneTree; ENSGT00940000153309; -.
DR   InParanoid; P05783; -.
DR   OMA; YRASSIH; -.
DR   OrthoDB; 4640531at2759; -.
DR   PhylomeDB; P05783; -.
DR   TreeFam; TF332742; -.
DR   PathwayCommons; P05783; -.
DR   Reactome; R-HSA-6805567; Keratinization.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   SignaLink; P05783; -.
DR   SIGNOR; P05783; -.
DR   BioGRID-ORCS; 3875; 105 hits in 1166 CRISPR screens.
DR   ChiTaRS; KRT18; human.
DR   GeneWiki; Keratin_18; -.
DR   GenomeRNAi; 3875; -.
DR   Pharos; P05783; Tbio.
DR   PRO; PR:P05783; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P05783; protein.
DR   Bgee; ENSG00000111057; Expressed in endometrium epithelium and 171 other tissues.
DR   ExpressionAtlas; P05783; baseline and differential.
DR   Genevisible; P05783; HS.
DR   GO; GO:0005912; C:adherens junction; HDA:BHF-UCL.
DR   GO; GO:0071944; C:cell periphery; IEA:Ensembl.
DR   GO; GO:0034451; C:centriolar satellite; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005882; C:intermediate filament; IDA:BHF-UCL.
DR   GO; GO:0045095; C:keratin filament; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; HDA:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043001; P:Golgi to plasma membrane protein transport; IDA:UniProtKB.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0045104; P:intermediate filament cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR002957; Keratin_I.
DR   PANTHER; PTHR23239; INTERMEDIATE FILAMENT; 1.
DR   PANTHER; PTHR23239:SF349; KERATIN, TYPE I CYTOSKELETAL 18; 1.
DR   Pfam; PF00038; Filament; 1.
DR   PRINTS; PR01248; TYPE1KERATIN.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Cell cycle; Coiled coil; Cytoplasm; Direct protein sequencing;
KW   Disease variant; Glycoprotein; Host-virus interaction;
KW   Intermediate filament; Isopeptide bond; Keratin; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:7538124"
FT   CHAIN           2..430
FT                   /note="Keratin, type I cytoskeletal 18"
FT                   /id="PRO_0000063666"
FT   DOMAIN          80..391
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   REGION          2..79
FT                   /note="Head"
FT   REGION          70..373
FT                   /note="Necessary for interaction with PNN"
FT                   /evidence="ECO:0000269|PubMed:10809736"
FT   REGION          77..128
FT                   /note="Interaction with TRADD"
FT                   /evidence="ECO:0000269|PubMed:11684708"
FT   REGION          80..115
FT                   /note="Coil 1A"
FT   REGION          116..132
FT                   /note="Linker 1"
FT   REGION          133..224
FT                   /note="Coil 1B"
FT   REGION          225..248
FT                   /note="Linker 12"
FT   REGION          243..391
FT                   /note="Interaction with DNAJB6"
FT                   /evidence="ECO:0000269|PubMed:10954706"
FT   REGION          249..387
FT                   /note="Coil 2"
FT   REGION          388..430
FT                   /note="Tail"
FT   SITE            238..239
FT                   /note="Cleavage; by caspase-3, caspase-6 or caspase-7"
FT   SITE            271
FT                   /note="Stutter"
FT   SITE            331
FT                   /note="Stutter"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|PubMed:7538124"
FT   MOD_RES         7
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         15
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         18
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         30
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P05784"
FT   MOD_RES         31
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P05784"
FT   MOD_RES         34
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:15368451,
FT                   ECO:0000269|PubMed:9524113, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         36
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05784"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         45
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         49
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         51
FT                   /note="Phosphoserine; by MAPKAPK2 and MAPKAPK3"
FT                   /evidence="ECO:0000250|UniProtKB:P05784"
FT   MOD_RES         52
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         53
FT                   /note="Phosphoserine; by CAMK, PKC/PRKCE and AURKA"
FT                   /evidence="ECO:0000269|PubMed:15368451,
FT                   ECO:0000269|PubMed:16424149, ECO:0000269|PubMed:7523419"
FT   MOD_RES         55
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         60
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         65
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         93
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         131
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         177
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         302
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         399
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         401
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         404
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         426
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CARBOHYD        30
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20729549,
FT                   ECO:0000269|PubMed:7538124"
FT                   /id="CAR_000175"
FT   CARBOHYD        31
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20729549,
FT                   ECO:0000269|PubMed:7538124"
FT                   /id="CAR_000193"
FT   CARBOHYD        49
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20729549,
FT                   ECO:0000269|PubMed:7538124"
FT                   /id="CAR_000194"
FT   CROSSLNK        81
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        247
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        370
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        372
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        417
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        426
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        426
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         103
FT                   /note="T -> A (in CIRRH; dbSNP:rs61136606)"
FT                   /evidence="ECO:0000269|PubMed:12724528"
FT                   /id="VAR_023054"
FT   VARIANT         128
FT                   /note="H -> L (in CIRRH; interfers with the ability to form
FT                   normal filaments; dbSNP:rs57758506)"
FT                   /evidence="ECO:0000269|PubMed:12724528,
FT                   ECO:0000269|PubMed:9011570"
FT                   /id="VAR_003852"
FT   VARIANT         230
FT                   /note="S -> T (in dbSNP:rs58472472)"
FT                   /evidence="ECO:0000269|PubMed:12724528"
FT                   /id="VAR_023055"
FT   VARIANT         261
FT                   /note="R -> Q (in CIRRH; dbSNP:rs57354642)"
FT                   /evidence="ECO:0000269|PubMed:12724528"
FT                   /id="VAR_023056"
FT   VARIANT         340
FT                   /note="G -> R (in CIRRH; dbSNP:rs57370769)"
FT                   /evidence="ECO:0000269|PubMed:12724528"
FT                   /id="VAR_023057"
FT   MUTAGEN         2
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-7 and A-10."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         7
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-2 and A-10."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         10
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-2 and A-7."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         15
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-18 and A-23. Abolishes phosphorylation; when
FT                   associated with A-18; A-34; A-47; A-49; A-51 and A-53."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         18
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-15 and A-23. Abolishes phosphorylation; when
FT                   associated with A-15; A-34; A-47; A-49; A-51 and A-53."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         23
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-15 and A-18."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         30
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-31 and A-34, or with A-31; A-44 and A-51. Abolishes
FT                   glycosylation but does not affect binding to YWHAE and
FT                   YWHAZ; when associated with A-31 and A-49."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:7538124"
FT   MUTAGEN         31
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-30 and A-34, or with A-30; A-44 and A-51. Abolishes
FT                   glycosylation but does not affect binding to YWHAE and
FT                   YWHAZ; when associated with A-30 and A-49."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:7538124"
FT   MUTAGEN         34
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-30 and A-31. Abolishes phosphorylation; when
FT                   associated with A-15; A-18; A-47; A-49; A-51 and A-53.
FT                   Abolishes binding to YWHAE and YWHAZ; and when associated
FT                   with A-53."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:9524113"
FT   MUTAGEN         34
FT                   /note="S->D,E: Abolishes binding to YWHAE and YWHAZ."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:9524113"
FT   MUTAGEN         42
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-44."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         44
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-42, or with A-30; A-31 and A-51."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         47
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-49. Abolishes phosphorylation; when associated with
FT                   A-49; A-51 and A-53, or with A-15; A-18; A-34; A-49; A-51
FT                   and A-53."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         49
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-47. Abolishes phosphorylation; when associated with
FT                   A-47; A-51 and A-53, or with A-15; A-18; A-34; A-47; A-51
FT                   and A-53. Abolishes glycosylation but does not affect
FT                   binding to YWHAE and YWHAZ; when associated with A-30 and
FT                   A-31."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:7538124"
FT   MUTAGEN         51
FT                   /note="S->A: No effect on phosphorylation; when associated
FT                   with A-30; A-31 and A-47. Abolishes phosphorylation; when
FT                   associated with A-47; A-49 and A-53, or with A-15; A-18;
FT                   A-34; A-47; A-49 and A-53."
FT                   /evidence="ECO:0000269|PubMed:7523419"
FT   MUTAGEN         53
FT                   /note="S->A: Abolishes phosphorylation; when associated
FT                   with A-47; A-49 and A-51, or with A-15; A-18; A-34; A-47;
FT                   A-49 and A-51. Abolishes binding to YWHAE and YWHAZ; when
FT                   associated with A-34. No effect on caspase cleavage during
FT                   apoptosis."
FT                   /evidence="ECO:0000269|PubMed:7523419,
FT                   ECO:0000269|PubMed:9298992, ECO:0000269|PubMed:9524113"
FT   MUTAGEN         90
FT                   /note="R->C,H: In transgenic mice, induces marked
FT                   disruption of liver and pancreas keratin filament network.
FT                   Increases phosphorylation and glycosylation."
FT                   /evidence="ECO:0000269|PubMed:8522591"
FT   MUTAGEN         238
FT                   /note="D->E: Prevents cleavage by caspase-6 during
FT                   apoptosis. Induces aggregates of keratin filaments in an
FT                   altered organization."
FT                   /evidence="ECO:0000269|PubMed:9298992"
FT   CONFLICT        168
FT                   /note="Y -> H (in Ref. 5; AAH00698)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        202
FT                   /note="E -> Q (in Ref. 8; CAA31369)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        208
FT                   /note="E -> G (in Ref. 3; BAD96813)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        246
FT                   /note="A -> S (in Ref. 8; CAA31369)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        309
FT                   /note="D -> R (in Ref. 8; CAA31369)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        312
FT                   /note="S -> R (in Ref. 8; CAA31369)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   430 AA;  48058 MW;  1E5604C6BCC7A17A CRC64;
     MSFTTRSTFS TNYRSLGSVQ APSYGARPVS SAASVYAGAG GSGSRISVSR STSFRGGMGS
     GGLATGIAGG LAGMGGIQNE KETMQSLNDR LASYLDRVRS LETENRRLES KIREHLEKKG
     PQVRDWSHYF KIIEDLRAQI FANTVDNARI VLQIDNARLA ADDFRVKYET ELAMRQSVEN
     DIHGLRKVID DTNITRLQLE TEIEALKEEL LFMKKNHEEE VKGLQAQIAS SGLTVEVDAP
     KSQDLAKIMA DIRAQYDELA RKNREELDKY WSQQIEESTT VVTTQSAEVG AAETTLTELR
     RTVQSLEIDL DSMRNLKASL ENSLREVEAR YALQMEQLNG ILLHLESELA QTRAEGQRQA
     QEYEALLNIK VKLEAEIATY RRLLEDGEDF NLGDALDSSN SMQTIQKTTT RRIVDGKVVS
     ETNDTKVLRH
//
